SER
Serina Therapeutics, Inc.
Next earnings Aug 3, 2026 · consensus $-0.46 EPS
Last earnings +10.3% on 2026-05-14
$1.81
▼ -0.55%$1.81▼ -66.36%
over 1Y
L $1.28EODHDH $6.17
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.5%
1W-4.2%
1M+0.6%
3M-20.3%
YTD-12.9%
1Y-66.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 5 analysts
Buy
Revenue grew 132.1% YoY; but unprofitable (net margin -14755.4%).
Serina Therapeutics, Inc. shows $130K in FY2025 revenue (+132.1% YoY), a -14755.4% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $144K | $34.0K | $3.15M | $56.0K | $130K |
| Gross profit | $125K | $21.0K | $102K | — | — |
| Operating income | -$7.93M | -$6.97M | -$3.13M | -$17.0M | -$24.0M |
| Net income | -$8.68M | -$10.5M | $5.27M | -$11.1M | -$19.2M |
| Diluted EPS | — | -$9.70 | $0.73 | -$1.51 | -$1.91 |
| Net margin | -6024.3% | -30770.6% | 167.1% | -19894.6% | -14755.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$37.4M
EV / EBITDA—
EV / Sales287.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-86.1%
FCF yield-80.8%
Quality & risk
ROIC (est.)—
Free cash flow-$18.0M
Total debt$18.1M
Net cash-$15.1M
Altman Z-Score-21.83 distress
Piotroski F-Score3/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+24.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-03-27). Worth a closer look.
- 8-K Charter / bylaws change2026-06-24
- S-3 Shelf registration (potential raise)2026-05-22
- 8-K Earnings results2026-05-14
- 10-Q Quarterly report2026-05-14
- DEF 14A Proxy statement2026-04-27
- 8-K Officer / director change2026-04-21
- 10-K/A Restated periodic report2026-03-27
- 8-K Earnings results2026-03-25
- 10-K Annual report2026-03-25
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-172026-06-24open ↗4Period ending 2026-05-222026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-112026-06-15open ↗EFFECTFiling2026-06-03open ↗4Period ending 2026-05-262026-05-27open ↗4Period ending 2026-05-212026-05-26open ↗4Period ending 2026-05-212026-05-26open ↗4Period ending 2026-05-212026-05-26open ↗
Frequently asked
- Is Serina Therapeutics, Inc. (SER) a buy?
- SER currently carries a Avoid rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 132.1% YoY; but unprofitable (net margin -14755.4%).
- What is Serina Therapeutics, Inc.'s quality score?
- SER scores 27.999999999999996/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001708599, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 8:10:46 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.